Home › Trials › NCT06671496

Evaluating Zasocitinib for Psoriatic Arthritis Treatment

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

PHASE3 · Takeda · NCT06671496

This study is testing a new drug called zasocitinib to see if it helps adults with active psoriatic arthritis feel better, no matter what treatments they've tried before.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorTakeda (industry)
Drugs / interventionszasocitinib
Locations122 sites (Mesa, Arizona and 121 other locations)
Trial IDNCT06671496 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of zasocitinib (TAK-279) in adults with active psoriatic arthritis (PsA), regardless of their previous treatment history with biologic medicines. Participants will receive either the drug or a placebo over a period of up to 60 weeks. The study aims to assess how well the treatment works based on the participants' prior experiences with other therapies. The trial includes individuals who meet specific criteria related to their disease characteristics and treatment responses.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with active psoriatic arthritis and a history of inadequate response to previous treatments.

Not a fit: Patients who do not have active psoriatic arthritis or have not previously tried any treatments for the condition may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from psoriatic arthritis.

How similar studies have performed: Other studies have shown promise with similar drug therapies for psoriatic arthritis, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Age:

1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF).

   Disease Characteristics:
2. The participant has a diagnosis of PsA.
3. The participant must have signs and symptoms of PsA for at least 3 months prior to screening.
4. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
5. The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.
6. The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

   Medications for PsA:
7. The participant has had at least one of the following:

   1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union \[EU\]/ European Economic Area \[EEA\]), OR
   2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD), OR
   3. Biological disease-modifying antirheumatic drug (DMARD)-inadequate response (Bio-IR): Inadequate response to up to 2 biologic DMARDs.

Exclusion Criteria:

PsA and PsO:

1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Where this trial is running

Mesa, Arizona and 121 other locations

+72 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Psoriatic Arthritis, Drug Therapy, Latitude Research Program, Latitude PsA, Latitude PsA-3002

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.